- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02745756
A Combined Cell Therapy Approach to the Treatment of Neuroblastoma
Study Overview
Status
Conditions
Detailed Description
All patients who are enrolled in this study will receive all treatment at All Children's Hospital which is located at 501 6th Ave South, St. Petersburg, FL 33701. This includes autologous cell donation by apheresis, high dose cytotoxic therapy conditioning for autologous HPC transplant, post-transplant follow-up care, and all administration of dendritic cell vaccines and blood draws for post therapy immunological monitoring.
All preparation of cellular products, including hematopoietic progenitor cell products for autologous transplantation, and dendritic cell vaccine products, will be carried out in the Cell Therapy Facility located within the Moffitt Cancer Center, which is located at 12902 Magnolia Drive, Tampa, FL 33612.
Study Type
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must have a histological diagnosis of neuroblastoma or ganglioneuroblastoma and be either newly diagnosed with high risk disease or have failed previous treatment: Patients who have failed previous treatment may have had no more than one earlier autologous HPC transplant.
- Participant is expected to undergo autologous HPC transplantation that is consistent with standard of care.
- Must have the presence of residual resectable disease for which surgery is clinically indicated, and will be performed at Johns Hopkins All Children's Hospital.
Exclusion Criteria:
- Not an eligible candidate for collection by apheresis or HPC transplant.
- History of autoimmune disorder or immune deficiency disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combined Cell Therapy
Hematopoietic progenitor cell (HPC) transplant (HPCT) with autologous tumor cell lysate and keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine.
|
Autologous Hematopoietic Progenitor Cell (HPC) Transplant (HPCT).
Blood stem cells will be collected by apheresis during the induction phase as part of standard treatment.
During apheresis, the participant's blood is collected into a machine that filters out the stem cells and the filtered blood is returned to their body.
The stem cells will be separated by the type of protein within the cells.
Only the stem cells with a protein called CD34 will be used for the stem cell transplant.
Other Names:
Keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine.
Post-transplant vaccine days: +14, +28, +56 (± 10 days), +84 (± 10 days).
Vaccines will be administered by intradermal injection of 0.5 mL at two nodal basins.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of Sufficient Tumor Cell Lysate and Dendritic Cells
Time Frame: Up to 1 year
|
The feasibility of manufacturing both a hematopoietic progenitor cell graft and multiple tumor lysate pulsed dendritic cell vaccine treatments from the same starting apheresis product, culminating in delivery of the vaccines in the immediate period following myeloablative therapy and autologous hematopoietic progenitor cell transplant period (autoHPCT).
For what fraction of eligible patients can sufficient tumor cell lysate and dendritic cells, necessary for the production of the dendritic cell vaccines, be obtained?
From what fraction would it be possible to make additional vaccines?
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of Dendritic Cell Related Adverse Events
Time Frame: Up to 1 year
|
Toxicities resulting from the administration of dendritic cell vaccines in the immediate post hematopoietic cell graft period.
|
Up to 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Anti-tumor Effect
Time Frame: Up to 1 year
|
Whether a discernable anti-tumor effect resulting from autoHPCT therapy combined with dendritic cell vaccine therapy can be detected, either through monitoring of the patient's immune system for evidence of tumor specific immunity, or by monitoring for measureable clinical responses.
|
Up to 1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Shari Pilon-Thomas, Ph.D., H. Lee Moffitt Cancer Center and Research Institute
- Principal Investigator: Gregory Hale, M.D., Johns Hopkins All Children's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors, Primitive, Peripheral
- Neuroblastoma
- Neoplasms, Nerve Tissue
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- MCC-17181
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms, Nerve Tissue
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Active, not recruitingOptic Nerve Sheath Tumors, BenignItaly
-
Oslo University HospitalMerck Sharp & Dohme LLCTerminatedMalignant Peripheral Nerve Sheath Tumour (MPNST)Norway
-
Memorial Sloan Kettering Cancer CenterAstex Pharmaceuticals, Inc.RecruitingMalignant Peripheral Nerve Sheath Tumors (MPNST)United States
-
Maastricht Radiation OncologyUniversity Medical Center Groningen; Erasmus Medical Center; Leiden University... and other collaboratorsRecruitingAstrocytoma | Adenoma | Ependymoma | Nerve Sheath Neoplasms | Ganglioglioma | Oligodendroglioma | Meningioma | Hemangiopericytoma | Craniopharyngioma | Germinoma | Neurilemmoma | Optic Nerve GliomaNetherlands
-
University of Texas Southwestern Medical CenterWithdrawnPeripheral Nerve TumorsUnited States
-
University of FloridaEpizyme, Inc.RecruitingPeripheral Nerve Sheath TumorUnited States
-
Polyganics BVCompleted
-
Washington University School of MedicineBoston's Children HospitalRecruitingMalignant Peripheral Nerve Sheath TumorsUnited States, Canada, United Kingdom, India
-
Gulam ManjiDaiichi SankyoActive, not recruitingSarcoma | Malignant Peripheral Nerve Sheath TumorsUnited States
-
Novartis PharmaceuticalsTerminatedMalignant Peripheral Nerve Sheath TumorsGermany
Clinical Trials on Autologous Hematopoietic Progenitor Cell Transplant
-
Stanford UniversityCompletedLeukemia, Lymphocytic, ChronicUnited States
-
Centro de Hematología y Medicina InternaEnrolling by invitation
-
Stanford UniversityCompletedLeukemia | Leukemia, Myelocytic, Acute | Blood and Marrow Transplant (BMT)United States
-
Stanford UniversityCompletedMultiple MyelomaUnited States
-
Medical College of WisconsinGenzyme, a Sanofi CompanyCompletedMultiple Myeloma | Bone Marrow Transplant ComplicationsUnited States
-
Gary A Levy, O. Ont. MD. FRCP AGAFOttawa Hospital Research InstituteCompletedComplication of Transplanted Organ, NosCanada
-
University of Colorado, DenverCompletedHyperglycemia | Hypoglycemia | Stem Cell Transplant ComplicationsUnited States
-
Center for International Blood and Marrow Transplant...National Cancer Institute (NCI); National Institutes of Health (NIH); National...RecruitingMyelofibrosisUnited States
-
Bioray LaboratoriesFirst Affiliated Hospital of Guangxi Medical UniversityNot yet recruiting
-
Bioray LaboratoriesNanfang Hospital, Southern Medical UniversityNot yet recruitingSickle Cell Disease